MarketVIEW: Hepatitis B virus vaccines

News provided by

Dec 24, 2013, 08:15 ET

NEW YORK, Dec. 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Hepatitis B virus vaccines

http://www.reportlinker.com/p01934498/MarketVIEW-Hepatitis-B-virus-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Hepatitis B virus (HBV) is transmitted by exposure to infectious blood or body fluids by percutaneous or mucosal means. Transmission occurs usually amongst adults exhibiting risk behaviours e.g. IDUs, MSM and heterosexuals with multiple partners although vertical transmission can occur from mother to child at birth. The HBV virus is more infectious than HIV and can cause chronic infection, resulting in cirrhosis of the liver, liver cancer, liver failure, and death. It is estimated that 2 billion people worldwide have been infected with the virus and about 600 000 people die every year due to the consequences of hepatitis B (WHO Figures).

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Hepatitis B Virus (HBV) vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult risk groups and infants vaccination (where policy in place). The product also includes three different scenarios for the potential penetration of Dynavax's new HBV vaccine Heplisav and gives estimates of potential revenues to 2030.

THIS PRODUCT IS A EXECUTIVE PRESENTATION + 3 MODELS

Author's note

Executive Summary

Heplisav: market revenues to 2030 ($m) – SCENARIO 1

Heplisav: market revenues to 2030 ($m) – SCENARIO 2

Heplisav: market revenues to 2030 ($m) – SCENARIO 3

Existing HBV vaccines: revenues by vaccine type

Existing HBV vaccines: revenues by market (all types)

Existing HBV vaccines: revenues by market (monovalent)

Existing HBV vaccines: revenues by market (Twinrix)

Existing HBV vaccines: revenues by risk group (all types)

Existing HBV vaccines: revenues by risk group (monovalent)

Existing HBV vaccines: revenues by risk group (Twinrix)

Existing HBV vaccines: volume (all types)

Commercial model: key assumptions

Overview of modeling strategy

Target populations

Healthcare workers: modeling strategy

Travelers: modeling strategy

Diabetics: modeling strategy, US

Infants: modeling strategy

Other "at risk" populations: modelling strategy

Pricing and reimbursement

Pricing assumptions

Reimbursement polices: per major risk group/country

Vaccine market share split per country

At risk populations per country

HBV vaccine coverage by country

HBV background

HBV epidemiology summary

HBV global epidemiology

US: incident cases and risk exposures

Europe: HBV incident cases

Hepatitis B vaccines and dosing schedules

Merck & Co and GSK hepatitis vaccine sales, 2005-2011

National HBV vaccine policies

Heplisav overview

Bibliography

About VacZine Analytics

Disclaimer

PAGES: ~65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand models (MS Excel-based)

Title sheet CHARTS – VALUE CHARTS – VOLUME Heplisav sales forecast Country value summary Value adults (all) Value adults (monovalent) Value (Twinrix) Volume Adult worksheets ? US (adults) Canada (adults) Australia (adults) France (adults) Germany (adults) Italy (adults) Spain (adults) UK (adults) Spain (adults) Adult worksheets ? US (infants) Canada (infants) Australia (infants) Europe universal (infants) Europe at risk (infants) Source material ? Births Total populations 18-49 yrs Global price summary At risk variables Public/private split Monovalent combi split ESRD incidence Trips to HBV endemic countries Travel market variables HBV cases US HBV cases US by risk group HBV cases US Diabetes Pneumo vaccine coverage Sales data Back page